NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
Clinical Trials
5 trialsNCT05064280 2025-10-09
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04729348 2025-07-25
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Massachusetts General Hospital
Phase 2 Terminated
NCT02592356 2024-03-05
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
Phase NA Completed
NCT03008369 2024-02-20
Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed